Radiotherapy

Phase 3Small molecule

GSK

Radiotherapy is one of 49 small molecule programs targeting Astrocytoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AstrocytomaActive, not recruiting

LymphomaActive, not recruiting

AstrocytomaPhase 3

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Radiotherapy

GSK

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Tafasitamab

Incyte

Preclinical

7 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

PEG-Intron

1 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Chemoradiotherapy

NCT05674305

Clinical

Trials by Indication[1]

Chemoradiotherapy1 trial

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Recruiting·FFudan University·Phase 3·NCT05674305·366 enrolled

Lymphoma1 trial

Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma

Unknown status·FFudan University·Phase 2·NCT01667302·30 enrolled

Astrocytoma1 trial

Radiotherapy for Malignant Astrocytomas in the Elderly

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00430911

Advanced NSCLC1 trial

Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03044626·101 enrolled

Head and Neck Cancer1 trial

Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

Completed· GSK logo

GSK·Phase 2·NCT00387127·67 enrolled

2 more indications

TED1 trial

Simultaneous Integrated Boost (SIB)- IMRT

Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT00389727·22 enrolled

Radiation Therapy1 trial

Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer

Unknown status·AAUSL Romagna Rimini·Phase 2·NCT04083365·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Radiotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radiotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radiotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Radiotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Chemoradiotherapy1 trial

Lymphoma1 trial

Astrocytoma1 trial

Advanced NSCLC1 trial

Head and Neck Cancer1 trial

TED1 trial

Radiation Therapy1 trial

References

Drug Info

Quick Facts

Related News